Comparison of first-trimester contingent screening strategies for Down syndrome

Ultrasound in Obstetrics and Gynecology

Volumn 35, Issue 3, 2010, Pages 286-291

  Sahota, D S ^a   Leung, T Y ^a   Chan, L W ^a   Law, L W ^a   Fung, T Y ^a   Chen, M ^a   Lau, T K ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Combined screening; Contingent screening; Nasal bone; Nuchal translucency; Serum biochemistry; Trisomy 21

Indexed keywords

BIOLOGICAL MARKER; CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ARTICLE; BLOOD; COMPARATIVE STUDY; DOWN SYNDROME; FEMALE; FIRST TRIMESTER PREGNANCY; GENETICS; GESTATIONAL AGE; HUMAN; LABORATORY DIAGNOSIS; MATERNAL AGE; METHODOLOGY; NUCHAL TRANSLUCENCY MEASUREMENT; PREDICTION AND FORECASTING; PREGNANCY; RETROSPECTIVE STUDY; UNITED KINGDOM;

BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DOWN SYNDROME; ENGLAND; FALSE POSITIVE REACTIONS; FEMALE; GESTATIONAL AGE; HUMANS; MATERNAL AGE; NUCHAL TRANSLUCENCY MEASUREMENT; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; RETROSPECTIVE STUDIES; WALES;

EID: 77949636934     PISSN: 09607692     EISSN: 14690705     Source Type: Journal    
DOI: 10.1002/uog.7549     Document Type: Article

References (29)

1. Nicolaides KH. First-trimester screening for chromosomal abnormalities. Semin Perinatol 2005; 29: 190-194.
2. Leung TY, Chan LW, Leung TN, Fung TY, Sahota DS, Spencer K, Lau TK. First-trimester combined screening for trisomy 21 in a predominantly Chinese population. Ultrasound Obstet Gynecol 2007; 29: 14-17.
3. Logghe H, Cuckle H, Sehmi I. Centre-specific ultrasound nuchal translucency medians needed for Down syndrome screening. Prenat Diagn 2003; 23: 389-392.
4. Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters. N Engl J Med 1999; 341: 461-467.
5. Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol 2005; 25: 221-226.
6. Wright D, Bradbury I, Cuckle H, Gardosi J, Tonks A, Standing S, Benn P. Three-stage contingent screening for Down syndrome. Prenat Diagn 2006; 26: 528-534.
7. Benn P, Wright D, Cuckle H. Practical strategies in contingent sequential screening for Down syndrome. Prenat Diagn 2005; 25: 645-652.
8. Christiansen M, Olesen Larsen S. An increase in cost- effectiveness of first trimester maternal screening programmes for fetal chromosome anomalies is obtained by contingent testing. Prenat Diagn 2002; 22: 482-486.
9. Vadiveloo T, Crossley JA, Aitken DA. First-trimester contingent screening for Down syndrome can reduce the number of nuchal translucency measurements required. Prenat Diagn 2009; 29: 79-82.
10. Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 2008; 31: 493-502.
11. Wright D, Kagan KO, Molina FS, Gazzoni A, Nicolaides KH. A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol 2008; 31: 376-383.
12. Cuckle HS, Wald NJ, Thompson SG. Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol 1987; 94: 387-402.
13. Snijders RJ, Sundberg K, Holzgreve W, Henry G, Nicolaides KH. Maternal age- and gestation-specific risk for trisomy 21. Ultrasound Obstet Gynecol 1999; 13: 167-170.
14. Sahota DS, Leung TY, Leung TN, Chan OK, Lau TK. Fetal crown-rump length and estimation of gestational age in an ethnic Chinese population. Ultrasound Obstet Gynecol 2009; 33: 157-160.
15. Sahota DS, Leung TY, Fung TY, Chan LW, Law LW, Lau TK. Medians and correction factors for biochemical and ultrasound markers in Chinese women undergoing first-trimester screening for trisomy 21. Ultrasound Obstet Gynecol 2009; 33: 387-393.
16. Leung TY, Sahota D, Chan LW, Law LW, Fung TY, Lau TK. Fetal nasal bone status in Chinese women undergoing firsttrimester screening for trisomy 21. Am J Obstet Gynecol 2008; 199: 521.e1-5.
17. Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 2008; 31: 618-624.
18. Kagan KO, Cicero S, Staboulidou I, Wright D, Nicolaides KH. Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11 -13 weeks of gestation. Ultrasound Obstet Gynecol 2009; 33: 259-264.
19. Cicero S, Avgidou K, Rembouskos G, Kagan KO, Nicolaides KH. Nasal bone in first-trimester screening for trisomy 21. Am J Obstet Gynecol 2006; 195: 109-114.
20. Office for National Statistics. Birth Statistics. Review of the Registrar General on births and patterns of family building in England and Wales. Series FM1, Nos 29-31. Stationery Office: London, 2002.
21. Leung TY, Chan LW, Leung TN, Fung TY, Sahota DS, Spencer K, Lau TK. First-trimester combined screening for trisomy 21 in a predominantly Chinese population. Ultrasound Obstet Gynecol 2007; 29: 14-17.
22. Leung TY, Chan LW, Law LW, Sahota DS, Fung TY, Leung TN, Lau TK. First trimester combined screening for Trisomy 21 in Hong Kong: outcome of the first 10,000 cases. J Matern Fetal Neonatal Med 2009; 22: 300-304.
23. Spencer K, Crossley JA, Aitken DA, Nix AB, Dunstan FD, Williams K. Temporal changes in maternal serum biochemical markers of trisomy 21 across the first and second trimester of pregnancy. Ann Clin Biochem 2002; 39: 567-576.
24. Laigaard J, Spencer K, Christiansen M, Cowans NJ, Larsen SO, Pedersen BN, Wewer UM. ADAM 12 as a first-trimester maternal serum marker in screening for Down syndrome. Prenat Diagn 2006; 26: 973-979.
25. Christiansen M, Nørgaard-Pedersen B. Inhibin A is a maternal serum marker for Down's syndrome early in the first trimester. Clin Genet 2005; 68: 35-39.
26. Down's Syndrome Quality Assurance Support Service (DQASS). QA of the MOM letter. http://fetalanomaly.screeningnhs.uk/getdata.php?id=10707 accessed on 1/2/2009.
27. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technol Assess 2003; 7: 1-77.
28. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Berkowitz RL, Gross SJ, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Dukes K, Bianchi DW, Rudnicka AR, Hackshaw AK, Lambert-Messerlian G, Wald NJ, D'Alton ME; First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium. First-trimester or second- trimester screening, or both, for Down's syndrome. N Engl J Med 2005; 353: 2001-2011.
29. Cuckle HS, Malone FD, Wright D, Porter TF, Nyberg DA, Comstock CH, Saade GR, Berkowitz RL, Ferreira JC, Dugoff L, Craigo SD, Timor IE, Carr SR, Wolfe HM, D'Alton ME. Contingent screening for Down syndrome - results from the FaSTER trial. Prenat Diagn 2008; 28: 89-94.